82 related articles for article (PubMed ID: 8650558)
1. Merit, quality, and the SBIR program.
Baron J
Science; 1996 Jun; 272(5269):1723-4. PubMed ID: 8650558
[No Abstract] [Full Text] [Related]
2. Merit, quality, and the SBIR program.
Whalen RL
Science; 1996 Jun; 272(5269):1725. PubMed ID: 8650560
[No Abstract] [Full Text] [Related]
3. SBIR program. Researchers fight against bigger slice to small business.
Mervis J
Science; 2009 Jul; 325(5936):18. PubMed ID: 19574355
[No Abstract] [Full Text] [Related]
4. Merit, quality, and the SBIR.
Laughlin R
Science; 1996 Jun; 272(5269):1724-5. PubMed ID: 8650559
[No Abstract] [Full Text] [Related]
5. Merit, quality, and the SBIR.
Bradshaw RA
Science; 1996 Jun; 272(5269):1723. PubMed ID: 8650556
[No Abstract] [Full Text] [Related]
6. A $1 billion 'tax' on R&D funds.
Mervis J
Science; 1996 May; 272(5264):942-4. PubMed ID: 8638132
[No Abstract] [Full Text] [Related]
7. Do biomaterials really mean business?
Waltz E
Nat Biotechnol; 2008 Aug; 26(8):851-3. PubMed ID: 18688229
[No Abstract] [Full Text] [Related]
8. Fundraising 101: why seek private funding?
Duyck GP
J Public Health Manag Pract; 2008; 14(2):199-201. PubMed ID: 18287928
[No Abstract] [Full Text] [Related]
9. Startups hope federal study fixes SBIR flaws.
Basu P
Nat Biotechnol; 2004 Jun; 22(6):644. PubMed ID: 15175671
[No Abstract] [Full Text] [Related]
10. Research funding. France hatches 67 California wannabes.
Enserink M
Science; 2005 Jul; 309(5734):547. PubMed ID: 16040682
[No Abstract] [Full Text] [Related]
11. Research commercialization--SBIR is good business.
Pool R
Nature; 1991 Oct; 353(6344):488. PubMed ID: 1922348
[No Abstract] [Full Text] [Related]
12. The case for publicly funded research on the ethical, environmental, economic, legal and social issues raised by nanoscience and nanotechnology (NE3LS).
Sheremeta L; Daar AS
Health Law Rev; 2004; 12(3):74-7. PubMed ID: 15706709
[No Abstract] [Full Text] [Related]
13. Towards a 'knowledge nation'.
Nature; 2001 Jun; 411(6838):619. PubMed ID: 11395723
[No Abstract] [Full Text] [Related]
14. Structural equation model for the evaluation of national funding on R&D project of SMEs in consideration with MBNQA criteria.
Sohn SY; Gyu Joo Y; Kyu Han H
Eval Program Plann; 2007 Feb; 30(1):10-20. PubMed ID: 17689310
[TBL] [Abstract][Full Text] [Related]
15. Capturing discovery.
Dagnone T; Gleeson F
Leadersh Health Serv; 1996; 5(3):34-8. PubMed ID: 10158409
[TBL] [Abstract][Full Text] [Related]
16. Transgenic crops. China takes a bumpy road from the lab to the field.
Yimin D; Mervis J
Science; 2002 Dec; 298(5602):2317-9. PubMed ID: 12493892
[No Abstract] [Full Text] [Related]
17. Investing in nanotechnology.
Paull R; Wolfe J; Hébert P; Sinkula M
Nat Biotechnol; 2003 Oct; 21(10):1144-7. PubMed ID: 14520393
[No Abstract] [Full Text] [Related]
18. [Requirements and needs--health between solidarity and commerce].
Resch KL
Forsch Komplementmed; 2009 Apr; 16(2):72-4. PubMed ID: 19420951
[No Abstract] [Full Text] [Related]
19. The socialization of risk. Medicare debate, bailouts speak volumes about corporate, government recklessness.
McLaughlin N
Mod Healthc; 2008 Jul; 38(29):20. PubMed ID: 18822566
[No Abstract] [Full Text] [Related]
20. Biotechnology. Stem cells lose market luster.
Vogel G
Science; 2003 Mar; 299(5614):1830-1. PubMed ID: 12649456
[No Abstract] [Full Text] [Related]
[Next] [New Search]
